Scarica l'app Stockscreener
5.2793
2.76%
0.2093
Precedente Chiudi:
$5.07
Aprire:
$5.04
Volume 24 ore:
63,343
Relative Volume:
1.31
Capitalizzazione di mercato:
$211.14M
Reddito:
$15.33M
Utile/perdita netta:
$-40.19M
Rapporto P/E:
-3.013
EPS:
-1.7522
Flusso di cassa netto:
-
1 W Prestazione:
-6.80%
1M Prestazione:
-6.80%
6M Prestazione:
+7.64%
1 anno Prestazione:
-9.55%
Intervallo 1D:
$5.04
$5.50
Intervallo di 1 settimana:
$5.00
$5.63
Portata 52W:
$3.50
$6.04
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Nome
Trisalus Life Sciences Inc
Settore
Industria
Telefono
415 336 8917
Indirizzo
6272 WEST 91ST AVENUE, WESTMINSTER
Confronta TLSI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
5.21 | 211.14M | 15.33M | -40.19M | 0 | -1.7522 |
|
ABT
Abbott Laboratories
|
133.68 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
106.27 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
392.96 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
85.68 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.65 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-13 | Iniziato | Lake Street | Buy |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-11-11 | Iniziato | ROTH MKM | Buy |
| 2024-10-25 | Iniziato | Northland Capital | Outperform |
| 2024-09-16 | Iniziato | Oppenheimer | Outperform |
| 2024-05-30 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Trisalus Life Sciences Inc Borsa (TLSI) Ultime notizie
TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Down 7.1% – Should You Sell? - Defense World
TriSalus shareholders elect directors, ratify auditor By Investing.com - Investing.com South Africa
TriSalus shareholders elect directors, ratify auditor - Investing.com
TriSalus Life Sciences Holds Annual Shareholder Meeting - TipRanks
Equities Analysts Set Expectations for TLSI FY2026 Earnings - Defense World
Cantor Fitzgerald maintains $9 target on TriSalus stock By Investing.com - Investing.com Nigeria
Millennium Management LLC Cuts Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
Cantor Fitzgerald maintains $9 target on TriSalus stock - Investing.com
Bank of America Corp DE Raises Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
TriSalus Launches TriNav FLX To Enhance Drug Delivery In Complex Peripheral Vessels - Nasdaq
TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Bluefield Daily Telegraph
TriSalus Unveils Next-Gen Cancer Treatment Device: New TriNav FLX Shows 28% Better Navigation - Stock Titan
Northern Trust Corp Has $161,000 Position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
Cantor Fitzgerald maintains TriSalus stock rating after CFO change By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains TriSalus stock rating after CFO change - Investing.com
TriSalus Life Sciences names new CFO - BizWest
TriSalus Life Sciences (TLSI) Plans to Offer 5.5M Shares of Comm - GuruFocus
TriSalus Life Sciences (TLSI) Names New Chief Financial Officer - GuruFocus
TriSalus Life Sciences (TLSI) Plans to Offer 5.5M Shares of Common Stock | TLSI Stock News - GuruFocus
TriSalus Life Sciences Appoints David Patience as CFO - marketscreener.com
TriSalus Life Sciences Appoints David Patience To Succeed James Young As CFO - Nasdaq
TriSalus Names David Patience Finance Chief as James Young Departs - MarketWatch
TriSalus Life Sciences appoints new CFO amid transition - Investing.com
TriSalus Life Sciences, Inc. Announces Chief Financial Officer Changes - marketscreener.com
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience - Business Wire
TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Up 3.9% – Should You Buy? - Defense World
Roth Capital Issues Negative Estimate for TLSI Earnings - Defense World
TLSI FY2025 EPS Estimate Reduced by Cantor Fitzgerald - Defense World
TriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable market - MSN
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2025 Earnings Call Transcript - MSN
Analysts Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) PT at $10.93 - Defense World
Trisalus Life Sciences Q1 2025 Earnings Call Highlights - TipRanks
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: TriSalus Life Sciences projects 50% revenue growth in Q1 2025 - Investing.com Nigeria
TriSalus Life Sciences Reports Strong Q1 2025 Growth - TipRanks
Transcript : TriSalus Life Sciences, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
TriSalus (TLSI) Exceeds Revenue Expectations in Q1 | TLSI Stock News - GuruFocus
Trisalus Life Sciences Q1 Pretax Profit USD -10.37 Million - marketscreener.com
TriSalus Life Sciences, Inc. Updates Earnings Guidance for the Year 2025 - marketscreener.com
TriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on Wednesday - Defense World
TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call - Business Wire
13,400 Shares in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Acquired by Renaissance Technologies LLC - Defense World
Geode Capital Management LLC Purchases 3,710 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
Northland maintains TriSalus stock with $12.50 target - Investing.com Australia
Northland maintains TriSalus stock with $12.50 target By Investing.com - Investing.com India
TLSI Reports Strong Revenue Growth in First Quarter of 2025 | TL - GuruFocus
TriSalus Life Sciences (TLSI) Secures $22M Investment and Plans Capital Restructuring | TLSI Stock News - GuruFocus
TriSalus Life Sciences secures $22 million in funding By Investing.com - Investing.com India
TriSalus Life Sciences secures $22 million in funding - Investing.com
TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results - Business Wire
Trisalus Life Sciences Inc Azioni (TLSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Trisalus Life Sciences Inc Azioni (TLSI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Devlin Jodi | Chief of Clinical Operations |
May 19 '25 |
Sale |
5.18 |
4,764 |
24,678 |
52,764 |
| Marshak Richard | Chief Commercial Officer |
May 19 '25 |
Sale |
5.18 |
6,597 |
34,172 |
69,101 |
| Stevens Jennifer | Chief Regulatory Officer |
May 19 '25 |
Sale |
5.18 |
8,704 |
45,087 |
77,640 |
| Young James Emmett | Chief Financial Officer |
Feb 05 '25 |
Buy |
5.65 |
6,000 |
33,900 |
30,000 |
| Szela Mary T | CEO AND PRESIDENT |
Jan 30 '25 |
Buy |
5.28 |
5,010 |
26,453 |
444,259 |
| Szela Mary T | CEO AND PRESIDENT |
Jan 29 '25 |
Buy |
5.03 |
5,030 |
25,301 |
439,249 |
| Szela Mary T | CEO AND PRESIDENT |
Jan 27 '25 |
Buy |
5.42 |
4,826 |
26,157 |
429,503 |
| Szela Mary T | CEO AND PRESIDENT |
Jan 28 '25 |
Buy |
5.12 |
4,716 |
24,146 |
434,219 |
| Murphy Sean | Chief Manuf, Strategy&Bus Dev. |
Jan 27 '25 |
Buy |
5.31 |
15,000 |
79,650 |
182,732 |
| Murphy Sean | Chief Manuf, Strategy&Bus Dev. |
Jan 28 '25 |
Buy |
5.17 |
15,000 |
77,550 |
197,732 |
0.23%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):